<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210546</url>
  </required_header>
  <id_info>
    <org_study_id>RF-2009-1539582</org_study_id>
    <nct_id>NCT02210546</nct_id>
  </id_info>
  <brief_title>Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk</brief_title>
  <acronym>MRIB</acronym>
  <official_title>A Multicenter Randomised Trial of Contrast-enhanced MR Imaging as a Breast Cancer Screening Tool Alternative to Mammography and Ultrasonography in Women at Intermediate Risk. Feasibility, and Short Term Results.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Paolo Bruzzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized controlled trial to evaluate the performance of MRI, in terms of
      sensitivity, specificity, and predictive value, in the screening of women at intermediate
      risk of breast cancer.

      Two surveillance programs will be compared. Women will be randomly assigned with a 1:1 ratio
      to:

        1. Yearly two-view mammography (Mx) and breast ultrasonography (US) or

        2. Yearly MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women, who, due to an increased risk of invasive breast cancer, are offered a specific
      surveillance program, as a supplement to the standard screening activities which in Italy are
      based on mammography every two years starting at age 50.Women will be randomly assigned to
      Yearly two-view mammography (Mx) and breast ultrasonography (US) or to Yearly MRI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of in situ and invasive breast cancers detected in the two arms of the study</measure>
    <time_frame>36 months</time_frame>
    <description>The performance of MRI will be evaluated , in terms of sensitivity, specificity, and predictive value, in the screening of women at intermediate risk of breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients per each clinical and pathological stage of invasive cancer detected in the two arms of the study</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the different histological characteristics of cancers detected in the two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of invasive diagnostic procedures in the two study arms.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of interval cancers in the two study arms.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of eligible women who accept to enter the study.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to the intervention in the two study arms.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average and interquartile range of the risk profiles computed according to IBIS Breast Cancer Risk Evaluation Tool in the two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cancers (in situ and invasive) detected in excess in the experimental arm compared to the conventional arm (overdiagnosis) after 10 years of follow up</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Magnetic Resonance Imaging (MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo MRI yearly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mammography (Mx) + ultrasonography (US)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo yearly two-view (Mx) and breast US</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <arm_group_label>Magnetic Resonance Imaging (MRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mammography (Mx) + ultrasonography (US)</intervention_name>
    <arm_group_label>Mammography (Mx) + ultrasonography (US)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 40-59 years with

          -  cumulative risk at 10 years of at least 5%, or a lifetime cumulative breast cancer
             risk ranging between 15% and 30% (equivalent to a relative risk of 2-6 as compared to
             a low risk woman of the same age). The lifetime cumulative risk of breast cancer will
             be computed using the IBIS Breast Cancer Risk Evaluation Tool
             (http://www.ems-trials.org/riskevaluator/); or mammographic density involving more
             than 75% of the breast area, based on the most recent mammogram. The evaluation of the
             composition of the mammary gland will be performed using the BI-RADS classification.
             Women with mammography in class 4 (i.e., &gt;75% of glandular component) will be eligible
             for randomization.

          -  Written Informed consent

        Exclusion Criteria:

          -  Signs or symptoms of breast cancer at enrolment;

          -  Previous diagnosis of ductal carcinoma in situ or invasive breast cancer;

          -  BRCA or p53 mutation carrier status;

          -  General contraindications to MRI (e.g. cardiac pacemaker, metal implants or history of
             severe allergic reaction after administration of contrast agent;

          -  Contraindications to any intravenous administration of contrast agent;

          -  Ongoing or planned pregnancy (for the duration of the study);

          -  Hormonal enhancement of ovarian function for assisted reproduction in the previous 3
             years

          -  Presence of breast implants;

          -  Previous diagnosis of cancer at any site;

          -  Life-threatening diseases;

          -  Mental disability precluding informed consent to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonella Petrillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale dei Tumori IRCCS Fondazione Pascale (Naples)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Belli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Gemelli (Rome)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Del Maschio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale san Raffaele (Milan)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Martincich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Candiolo (Turin)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Bazzocchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU S.Maria della Misericordia (Udine)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piero Panizza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori (Milan)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefania Montemezzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Integrata Verona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federica Pediconi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Policlinico Umberto I (Rome)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Corcione, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero Universitaria (Ferrara)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Calabrese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS AOU S. Martino-IST (Genoa)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Sardanelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Donato (Milan)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Bruzzi, MD</last_name>
    <phone>+390105558476</phone>
    <email>paolo.bruzzi@hsanmartino.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria S.Martino IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Bruzzi, MD</last_name>
      <phone>+390105558476</phone>
      <email>paolo.bruzzi@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Bruzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>August 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Prof. Paolo Bruzzi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>intermediate risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

